KEAP1 and neoplasm: Sirpiglenastat also demonstrated promising effects in a glutamine-dependent KRAS-mutant lung cancer model that carries KEAP1 mutations (88, 89) and reduced KEAP1-mutant tumor growth in both murine and patient-derived lung and squamous tumor models (88).